Malhotra A K, Goldman D, Mazzanti C, Clifton A, Breier A, Pickar D
Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-1380, USA.
Mol Psychiatry. 1998 Jul;3(4):328-32. doi: 10.1038/sj.mp.4000412.
The neurotransmitter serotonin has been implicated in the pathophysiology of psychosis. The serotonin transporter (5-HTT) plays a critical role in regulation of serotonergic function. A recently identified polymorphism in the promoter region of the 5-HTT gene (5-HTTLPR) produces significant differences in 5-HTT expression and function and was found to be associated with anxiety-related traits in healthy volunteers. We investigated whether 5-HTTLPR is associated with psychosis in neuroleptic-free schizophrenic or schizoaffective patients. Fifty patients with schizophrenia or schizoaffective disorder by DSM-III-R criteria were genotyped at 5-HTTLPR and underwent double-blind Brief Psychiatric Rating Scale (BPRS) ratings while neuroleptic-free for approximately 4 weeks. Patients with the 5-HTTLPR II genotype (n = 19) had significantly higher BPRS ratings for psychosis than patients with the Is (n = 25) or ss (n = 6) genotypes. Examination of individual items revealed a specific significant increase in intensity of hallucinations in patients with the 5-HTTLPR II genotpe. These data provide preliminary evidence for a role of serotonin in the pathophysiology of hallucinations and may represent the identification of an allelic variant that modifies the complex clinical presentation of schizophrenia.
神经递质5-羟色胺与精神病的病理生理学有关。5-羟色胺转运体(5-HTT)在5-羟色胺能功能的调节中起关键作用。最近在5-HTT基因启动子区域发现的一种多态性(5-HTTLPR)导致5-HTT表达和功能存在显著差异,并发现与健康志愿者的焦虑相关特质有关。我们调查了5-HTTLPR是否与未服用抗精神病药物的精神分裂症或分裂情感性障碍患者的精神病有关。根据DSM-III-R标准,对50例精神分裂症或分裂情感性障碍患者进行5-HTTLPR基因分型,并在未服用抗精神病药物约4周的情况下接受双盲简明精神病评定量表(BPRS)评分。5-HTTLPR II基因型患者(n = 19)的精神病BPRS评分显著高于Is基因型患者(n = 25)或ss基因型患者(n = 6)。对各个项目的检查显示,5-HTTLPR II基因型患者的幻觉强度有特定的显著增加。这些数据为5-羟色胺在幻觉病理生理学中的作用提供了初步证据,可能代表了一种等位基因变异的鉴定,该变异改变了精神分裂症复杂的临床表现。